$1.24
2.48% day before yesterday
Nasdaq, Jul 03, 10:53 pm CET
ISIN
US38341P1021
Symbol
GOSS
Sector
Industry

Gossamer Bio, Inc. Target price 2025 - Analyst rating & recommendation

Gossamer Bio, Inc. Classifications & Recommendation:

Buy
80%
Hold
20%

Gossamer Bio, Inc. Price Target

Target Price $8.16
Price $1.24
Potential
Number of Estimates 9
9 Analysts have issued a price target Gossamer Bio, Inc. 2026 . The average Gossamer Bio, Inc. target price is $8.16. This is higher than the current stock price. The highest price target is
$15.75 1,170.16%
register free of charge
, the lowest is .
A rating was issued by 15 analysts: 12 Analysts recommend Gossamer Bio, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Gossamer Bio, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Gossamer Bio, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 114.70 29.20
74.55%
EBITDA Margin -51.52% -501.21%
872.90%
Net Margin -49.29% -536.82%
989.21%

10 Analysts have issued a sales forecast Gossamer Bio, Inc. 2025 . The average Gossamer Bio, Inc. sales estimate is

$29.2m
Unlock
. This is
76.57% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$62.8m 49.60%
Unlock
, the lowest is
$9.7m 92.21%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $115m
2025
$29.2m 74.55%
Unlock
2026
$55.8m 91.14%
Unlock
2027
$133m 138.62%
Unlock
2028
$218m 63.34%
Unlock
2029
$361m 65.88%
Unlock
2030
$661m 83.15%
Unlock
2031
$646m 2.25%
Unlock
2032
$805m 24.65%
Unlock

5 Analysts have issued an Gossamer Bio, Inc. EBITDA forecast 2025. The average Gossamer Bio, Inc. EBITDA estimate is

$-146m
Unlock
. This is
170.04% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-120m 121.28%
Unlock
, the lowest is
$-169m 212.37%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-59.1m 65.68%
2025
$-146m 147.65%
Unlock
2026
$-43.6m 70.19%
Unlock
2027
$26.9m 161.56%
Unlock
2028
$68.6m 155.64%
Unlock
2029
$157m 128.37%
Unlock
2030
$297m 89.40%
Unlock

EBITDA Margin

2024 -51.52%
2025
-501.21% 872.90%
Unlock
2026
-78.17% 84.40%
Unlock
2027
20.17% 125.80%
Unlock
2028
31.56% 56.47%
Unlock
2029
43.45% 37.67%
Unlock
2030
44.94% 3.43%
Unlock

11 Gossamer Bio, Inc. Analysts have issued a net profit forecast 2025. The average Gossamer Bio, Inc. net profit estimate is

$-157m
Unlock
. This is
205.87% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-119m 132.81%
Unlock
, the lowest is
$-178m 247.66%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-56.5m 68.56%
2025
$-157m 177.25%
Unlock
2026
$-114m 26.97%
Unlock
2027
$-35.1m 69.33%
Unlock
2028
$-3.5m 90.09%
Unlock
2029
$53.9m 1,648.56%
Unlock
2030
$91.6m 69.88%
Unlock
2031
$161m 75.31%
Unlock
2032
$219m 36.46%
Unlock

Net Margin

2024 -49.29%
2025
-536.82% 989.21%
Unlock
2026
-205.11% 61.79%
Unlock
2027
-26.36% 87.15%
Unlock
2028
-1.60% 93.93%
Unlock
2029
14.94% 1,033.75%
Unlock
2030
13.85% 7.30%
Unlock
2031
24.85% 79.42%
Unlock
2032
27.20% 9.46%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.25 -0.69
78.81% 176.00%
P/E negative
EV/Sales 7.59

11 Analysts have issued a Gossamer Bio, Inc. forecast for earnings per share. The average Gossamer Bio, Inc. EPS is

$-0.69
Unlock
. This is
187.50% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.53 120.83%
Unlock
, the lowest is
$-0.78 225.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.25 78.81%
2025
$-0.69 176.00%
Unlock
2026
$-0.50 27.54%
Unlock
2027
$-0.15 70.00%
Unlock
2028
$-0.02 86.67%
Unlock
2029
$0.24 1,300.00%
Unlock
2030
$0.40 66.67%
Unlock
2031
$0.71 77.50%
Unlock
2032
$0.96 35.21%
Unlock

P/E ratio

Current -5.17 335.86%
2025
-1.80 65.16%
Unlock
2026
-2.46 36.67%
Unlock
2027
-8.03 226.42%
Unlock
2028
-81.05 909.34%
Unlock
2029
5.23 106.45%
Unlock
2030
3.08 41.11%
Unlock
2031
1.76 42.86%
Unlock
2032
1.29 26.70%
Unlock

Based on analysts' sales estimates for 2025, the Gossamer Bio, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.78
2025
7.59 326.56%
Unlock
2026
3.97 47.68%
Unlock
2027
1.66 58.09%
Unlock
2028
1.02 38.78%
Unlock
2029
0.61 39.72%
Unlock
2030
0.34 45.39%
Unlock
2031
0.34 2.30%
Unlock
2032
0.28 19.78%
Unlock

P/S ratio

Current
2025
9.65 326.72%
Unlock
2026
5.05 47.68%
Unlock
2027
2.12 58.09%
Unlock
2028
1.30 38.77%
Unlock
2029
0.78 39.72%
Unlock
2030
0.43 45.40%
Unlock
2031
0.44 2.32%
Unlock
2032
0.35 19.78%
Unlock

Current Gossamer Bio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Goldman Sachs
Locked
Locked
Locked May 16 2025
Wedbush
Locked
Locked
Locked May 16 2025
Goldman Sachs
Locked
Locked
Locked Apr 17 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 18 2025
Wedbush
Locked
Locked
Locked Mar 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 30 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 11 2024
Analyst Rating Date
Locked
Goldman Sachs:
Locked
Locked
May 16 2025
Locked
Wedbush:
Locked
Locked
May 16 2025
Locked
Goldman Sachs:
Locked
Locked
Apr 17 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 18 2025
Locked
Wedbush:
Locked
Locked
Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 30 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today